Who makes Kremezin granule?

Kremezin granule is developed by Daewon Pharmaceutical Co., Ltd..

What development phase is Kremezin granule in?

Kremezin granule is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Kremezin granule

Daewon Pharmaceutical Co., Ltd. · FDA-approved active Small molecule Quality 0/100

Kremezin granule, marketed by Daewon Pharmaceutical Co., Ltd., holds a significant position in its therapeutic segment. The key composition patent for Kremezin is set to expire in 2028, providing a clear period of market exclusivity. However, the lack of detailed revenue data and primary trial results poses a risk in assessing its long-term market sustainability and competitive edge.

At a glance

Generic name	Kremezin granule
Sponsor	Daewon Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results